The Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies. The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of academia derived ideas into practical application.

In short, it bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.

Read the full RFP